Agenus' cd137 agonist (agen2373) advances in the clinic, triggering milestone payment from gilead

Lexington, mass., april 05, 2022 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, today announced receipt of a $5m clinical milestone payment for agen2373 (conditionally active cd137 agonist). agen2373 is being evaluated in a phase 1b combination study with botensilimab (fc-enhanced anti-ctla-4), in melanoma patients who had relapsed on, or were refractory to, prior anti-pd-1 therapy.
AGEN Ratings Summary
AGEN Quant Ranking